Physician profile
Mohsin Ijaz
NPI 1407160369
$3,764.26
in general payments reported to CMS, 2019-2025
31 companies · $535 in 2025
The $535 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $754 · 2020: $1,159 · 2021: $544 · 2022: $34.66 · 2023: $21.12 · 2024: $717 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $943 · Travel and Lodging: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $942.96 |
| Travel and Lodging | $330.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,063.03 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $514.38 | 2019-2025 | Trelegy Ellipta |
| Intuitive Surgical, INC. | $330.43 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $306.52 | 2019-2021 | |
| Genzyme Corporation | $243.98 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $163.33 | 2019-2021 | |
| Mylan Specialty L.P. | $140.32 | 2019-2021 | |
| Inspire Medical Systems, INC. | $139.75 | 2024-2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $102.13 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $94.40 | 2019-2025 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $71.15 | 2021 | |
| Janssen Pharmaceuticals, INC | $67.35 | 2020-2023 | Xarelto |
| Insmed, INC. | $55.95 | 2020-2025 | Arikayce |
| Philips North America LLC | $52.65 | 2019-2025 | Vest Therapy Und |
| Merck Sharp & Dohme LLC | $48.04 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $44.13 | 2025 | Yupelri |
| Novartis Pharmaceuticals Corporation | $38.66 | 2021-2024 | |
| Amgen INC. | $35.72 | 2025 | Tezspire |
| Paratek Pharmaceuticals, INC. | $28.77 | 2025 | Nuzyra, Xhance |
| Atricure, INC. | $28.59 | 2024 | |
| Electromed, INC. | $28.26 | 2019-2021 | |
| Abiomed | $23.89 | 2025 | |
| Grifols USA, LLC | $22.37 | 2025 | Prolastin-C Liquid |
| Mallinckrodt Enterprises LLC | $19.31 | 2019 | |
| Circassia INC. | $18.02 | 2019 | |
| United Therapeutics Corporation | $17.41 | 2020 | |
| Baxter Healthcare | $16.89 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Pfizer INC. | $16.26 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.11 | 2024 | Glassia |
| Gilead Sciences, INC. | $14.29 | 2021 | |
| Veran Medical Technologies, INC. | $2.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohsin Ijaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.